GEN-Y Biologics has an exciting pipeline of other development opportunities beyond the SARS-CoV-2 and dengue assets, but, the initial focus for investment is on the dengue portfolio.
Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker Multi sales and from the early introduction of the dengue Point of Care diagnostic arriving late 2022/early 2023.
GEN-Y Biologics has an exciting pipeline of other development opportunities beyond the SARS-CoV-2 and dengue assets, but, the initial focus for investment is on the dengue portfolio.
Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker Multi sales and from the early introduction of the dengue Point of Care diagnostic arriving late 2022/early 2023.
For the investment perspective, virtually all the funding for this project has been made by the existing investors. Further investment is foreseen to be very small as GEN-Y Biologics implements the key strategies below
The ability to be able to swiftly and accurately diagnose Dengue infection serotype in the field/clinical/hospital will be a huge advance in understanding individual dengue risk and circulating disease. Importantly, it will provide the platform for swift diagnosis and treatment with the dengue fully humanised antibody therapy.
Investors will take advantage of the >US$ 20M non-dilutive investment that has been spent in taking the project to its status today!
From the investor perspective, the dengue portfolio opportunity can be summarised as below
If you would like to learn more about investment opportunities in GEN-Y Biologics, we would be like to hear from you.
Please send an mail to Dr Graham at our office in Singapore.
GEN-Y Biologics through the use of state-of-the-art technology and a unique antibody discovery platform discovers and develops fully human antibodies for use as therapies and diagnostics either alone or in collaboration with strategic partners.
GEN-Y Biologics through the use of state-of-the-art technology and a unique antibody discovery platform discovers and develops fully human antibodies for use as therapies and diagnostics either alone or in collaboration with strategic partners.